Chemoimmunotherapy of experimental hepatic metastases.
Previous studies from our laboratory have demonstrated that particulate glucan is efficacious in the therapy of a syngeneic murine reticulum cell sarcoma (M5706), which specifically metastasizes from its primary site to the liver. The present study was undertaken to examine the therapeutic efficacy of a newly developed soluble glucan, in combination with cyclophosphamide in the treatment of hepatic metastatic disease. Male C57Bl/6J mice were injected subcutaneously on Day 0 with 1 x 10(4) sarcoma cells. Glucan (200 mg per kg i.v.), cyclophosphamide (45 mg per kg i.p.) or glucan and cyclophosphamide were administered beginning on Day 20, when hepatic metastases were evident, and continued at 3-day intervals up to Day 50. Combined therapy with glucan and cyclophosphamide resulted in reduction of hepatic metastatic lesions on Day 36, compared to control. Survival data revealed that the combination of glucan and cyclophosphamide significantly (p less than 0.001) extended median survival time and the time to 100% mortality in an additive fashion, when compared to either therapy alone. Glucan-cyclophosphamide therapy was also effective in decreasing primary tumor weight to a level that was significantly (p less than 0.05) less than when therapy was initiated. In vitro studies revealed that Kupffer cell tumoricidal activity against sarcoma was increased (p less than 0.05) following glucan and cyclophosphamide. Glucan and cyclophosphamide also enhanced bone marrow proliferation and splenocyte response to mitogens in vitro. Additionally, glucan was observed to exert a direct cytostatic effect on sarcoma in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)
Williams
D L
DL
Department of Physiology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
Sherwood
E R
ER
McNamee
R B
RB
Jones
E L
EL
Browder
I W
IW
Di Luzio
N R
NR
D000818:Animals; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005936:Glucans / Q000008:administration & dosage* / Q000627:therapeutic use; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000556:secondary* / Q000628:therapy; D008297:Male; D051379:Mice; D011379:Prognosis
D005936:Glucans; D003520:Cyclophosphamide